C
Christine Baudelet
Researcher at Bristol-Myers Squibb
Publications - 24
Citations - 9781
Christine Baudelet is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Nivolumab & Ipilimumab. The author has an hindex of 16, co-authored 24 publications receiving 7789 citations.
Papers
More filters
Journal ArticleDOI
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
Julie R. Brahmer,Karen L. Reckamp,Paul Baas,Lucio Crinò,Wilfried Eberhardt,Elena Poddubskaya,Scott J. Antonia,Adam Pluzanski,Everett E. Vokes,Esther Holgado,David M. Waterhouse,Neal Ready,Justin F. Gainor,Osvaldo Arén Frontera,Libor Havel,Martin Steins,Marina Chiara Garassino,Joachim G.J.V. Aerts,Manuel Domine,Luis Paz-Ares,Martin Reck,Christine Baudelet,Christopher T. Harbison,Brian Lestini,David R. Spigel +24 more
TL;DR: Among patients with advanced, previously treated squamous-cell NSCLC, overall survival, response rate, and progression-free survival were significantly better with nivolumab than with docetaxel, regardless of PD-L1 expression level.
Journal ArticleDOI
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Naiyer A. Rizvi,Julien Mazieres,David Planchard,Thomas E. Stinchcombe,Grace K. Dy,Scott J. Antonia,Leora Horn,Hervé Lena,Elisa Minenza,Bertrand Mennecier,Gregory A. Otterson,Luis T. Campos,David R. Gandara,Benjamin Levy,Suresh G. Nair Md,Gérard Zalcman,Jürgen Wolf,Pierre Jean Souquet,Editta Baldini,Federico Cappuzzo,Christos Chouaid,Afshin Dowlati,Rachel E. Sanborn,Ariel Lopez-Chavez,Christian Grohe,Rudolf M. Huber,Christopher T. Harbison,Christine Baudelet,Brian Lestini,Suresh S. Ramalingam +29 more
TL;DR: Nivolumab has clinically meaningful activity and a manageable safety profile in previously treated patients with advanced, refractory, squamous non-small cell lung cancer and these data support the assessment of nivolumsab in randomised, controlled, phase 3 studies of first-line and second-line treatment.
Journal ArticleDOI
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Paul Baas,Arnaud Scherpereel,Anna K. Nowak,Nobukazu Fujimoto,Solange Peters,Anne S. Tsao,Aaron S. Mansfield,Sanjay Popat,Thierry Jahan,Scott J. Antonia,Youssef Oulkhouir,Yolanda Bautista,Robin Cornelissen,Laurent Greillier,Francesco Grossi,Dariusz M. Kowalski,Jerónimo Rodríguez-Cid,Praveen Aanur,Abderrahim Oukessou,Christine Baudelet,Gérard Zalcman +20 more
TL;DR: The CheckMate 743 trial as mentioned in this paper showed that nivolumab plus ipilimumab significantly improved overall survival compared to standard-of-care chemotherapy for non-small-cell lung cancer.
Journal ArticleDOI
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial.
Yi-Long Wu,Shun Lu,Ying Cheng,Caicun Zhou,Jie Wang,Tony Mok,Li Zhang,Hai Yan Tu,Lin Wu,Jifeng Feng,Yiping Zhang,Alexander Luft,Jianying Zhou,Zhiyong Ma,You Lu,Chengping Hu,Yuankai Shi,Christine Baudelet,Junliang Cai,Jianhua Chang +19 more
TL;DR: This is the first phase III study in a predominantly Chinese population reporting results with a programmed death 1 inhibitor and nivolumab improved OS versus docetaxel and results were consistent with global CheckMate 017 and 057 studies.
Journal ArticleDOI
Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
Richard S. Finn,Yoon-Koo Kang,Mary F. Mulcahy,Blase N. Polite,Ho Yeong Lim,Ian Walters,Christine Baudelet,Demetrios Manekas,Joong-Won Park +8 more
TL;DR: Brivanib had a manageable safety profile and is one of the first agents to show promising antitumor activity in advanced HCC patients treated with prior sorafenib.